SterilityW+DNCT02648555
A Lifestyle Intervention to Improve in Vitro Fertilization Results
A study testing Daily walking and Dietary recommendations in people with Sterility and Placenta; Implantation, run by Hospital dos Servidores do Estado do Rio de Janeiro at 1 site in Brazil.
Trial summary
Embryo adhesion and placentation depend on tissue plasminogen activator (tPA)-mediated activation of brain-derived neurotrophic factor, vascular endothelial growth factor and other growth factors, formation of hemidesmosomes, and degradation of extracellular matrix and basement membrane, either directly or by… Read more about this study
- Who is it for?
- Ages 18 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Sterility, Placenta; Implantation, Risk Reduction Behavior
- What is being tested?
- Daily walking and Dietary recommendations
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 240 participants
- Where
- 1 siteBrazil
- Study dates
- May 2016to May 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- women undergoing assisted reproduction
Who cannot join
- liver failure, kidney failure or other conditions that prevent the patient from eating proteins.
- multiple pregnancy.
- paraplegia, hemiplegia, arthropathy and other conditions that prevent the participant from exercising.
- participants lost to follow-up.
- conditions that may strongly affect pregnancy results, such as a serious accident
- participants assigned to non-intervention group following the recommendations given to intervention group.
Trial locations and contacts
1 site in 1 country.
Brazil1 site
Hospital Federal dos Servidores do Estado, Ministry of Health
Rio de Janeiro, Rio de Janeiro, 20221-903
Silvia Hoirisch-Clapauch, MD, PhD, +55-21-99973-7500, sclapauch@ig.com.br
Silvia Hoirisch-Clapauch, MD
About this study
Embryo adhesion and placentation depend on tissue plasminogen activator (tPA)-mediated activation of brain-derived neurotrophic factor, vascular endothelial growth factor and other growth factors, formation of hemidesmosomes, and degradation of extracellular matrix and basement membrane, either directly or by activating matrix metalloproteinases.
Since glucose and insulin stimulate release of a major tPA inhibitor by endothelial cells - plasminogen activator inhibitor (PAI)-1 - the investigators hypothesized that lifestyle interventions proven effective in maintaining glucose and insulin levels within the normal range would increase the take home baby rate in women undergoing assisted reproduction.
Read the detailed description
Tissue plasminogen activator (tPA) has a well-known role in the coagulation pathway. tPA converts plasminogen to plasmin. Plasmin dissolves fibrin clots, thus limiting thrombus formation to the site of vascular injury.
In the extravascular compartment, tPA is a pivotal mediator of tissue formation and remodeling. Due to its proteolytic activity, tPA participates in processes as diverse as embryo adhesion, placental angiogenesis and vasculogenesis, and neuronal plasticity. Embryo adhesion and placentation, for example, depend on tPA-mediated activation of brain-derived neurotrophic factor, vascular endothelial growth factor and other growth factors, formation of hemidesmosomes, and degradation of extracellular matrix and basement membrane, either directly or by activating matrix metalloproteinases.
Assuming low tPA activity would impair both blood clot dissolution and placentation, the investigators postulated that patients with consecutive first-trimester abortions would have a high prevalence of severe dysmenorrhea, accompanied by the passage of large clots.
In 2011, the investigators assessed the prevalence of severe dysmenorrhea during early adolescence in two groups. The first one was made of women with ≥ 2 consecutive first-trimester abortions, and the other, of women with ≥ 2 living births, and no losses or preterm deliveries. Severe dysmenorrhea was defined as suprapubic menstrual cramp, intense enough to cause repeated absenteeism from school or fainting in the absence of analgesia. Early adolescents are unlikely to use contraceptives, or to have become pregnant, two situations that may reduce the pain. In this study, severe dysmenorrhea increased the chances of having consecutive first-trimester miscarriages by sevenfold (95% Confidence Interval: 3.4 to 14.1; p<0.001).
Since glucose and insulin stimulate release of a major tPA inhibitor by endothelial cells - plasminogen activator inhibitor (PAI)-1 - the investigators hypothesized that lifestyle interventions proven effective in maintaining glucose and insulin levels within the normal range would increase the take home baby rate in women undergoing assisted reproduction.
The protocol has already been tested at a Brazilian tertiary care center in women with unexplained consecutive first-trimester abortions, conceiving spontaneously. The objective of this study was to observe the impact of lifestyle interventions on the take home baby rate, and to observe if the intervention could reduce the prevalence of preeclampsia and neonatal hypoglycemia.
From 2011 to 2015, 480 patients aged 18 to 42 years with ≥ 2 consecutive first-trimester abortions documented by pathology or ultrasonography, were randomly assigned to protocol Walking and Diet (W+D) or to standard follow-up (controls). Women were enrolled independent of having had severe dysmenorrhea during adolescence. Patients assigned to protocol W+D were instructed to walk briskly for ≥ 40 minutes seven days a week. In addition, they were recommended to avoid high-carbohydrate meals such as snacks, candies, fiber-free juices, coconut water and sugar-sweetened beverages, and to eat two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Women with antiphospholipid antibodies, second- or third-trimester losses, multiple pregnancies, anatomical abnormalities that could increase the risk of first-trimester abortions, or any condition requiring a priori anticoagulation were excluded.
- Conditions
- Sterility, Placenta; Implantation, Risk Reduction Behavior, Lifestyle, Neonatal Hypoglycemia
- Being tested
- Daily walking, Dietary recommendations
- Medical subject headings
- Infertility, Risk Reduction Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Daily walkingBehavioural
Participants will be instructed to walk briskly for >40 minutes, 7 days a week.
Dietary recommendationsBehavioural
Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks.
Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron.
| Study group | Role | What they receive |
|---|---|---|
| Standard follow-up (controls) | No intervention | Given that depressive disorders may increase the risk of spontaneous abortions, antidepressants will be not discontinued. However, expectant mothers on paroxetine or sertraline, which have been reported to increase the incidence of cardiac malformations, will be switched to fluoxetine. |
| W+D protocol (lifestyle intervention) | Experimental | Daily walking and dietary recommendations. Expectant mothers on paroxetine or sertraline will be switched to fluoxetine Receives: Behavioral: Daily walking; Behavioral: Dietary recommendations |
What is being measured
The primary outcome is the main question the study is designed to answer.
The rate of viable pregnancies
Measured: two years
Secondary outcomes (10)
The rate of fist trimester losses
Measured: four years
The rate of second and third trimester losses
Measured: four years
The rate of preeclampsia, eclampsia and HELLP syndrome
Measured: four years
Cramps or bleeding during the first trimester requiring progesterone
Measured: four years
The rate of prematurity
Measured: four years
The rate of intrauterine growth restriction
Measured: four years
Maternal weight gain
Measured: four years
The rate of gestational diabetes
Measured: four years
The rate of neonatal hypoglycemia
Measured: four years
The rate of neonatal hyperbilirubinemia requiring phototherapy
Measured: four years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2016 (estimated)
- Study startMay 2016
- Primary completionMay 2018 (estimated)
- Study completionMay 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SterilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 240 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital dos Servidores do Estado do Rio de Janeiro
- Sponsor type
- Other government
- Collaborators
- Gaffree & Guinle Universitary Hospital
- Responsible party
- Principal investigator, Silvia Hoirisch Clapauch, Hospital dos Servidores do Estado do Rio de Janeiro
- Investigators
- Silvia Hoirisch-Clapauch, MD, PhD, Principal investigator, Hospital Federal dos Servidores do Estado, Ministry of Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02648555
- Sponsor's protocol ID
- Protocol W+D
- Acronym
- W+D
- Status last verified
- Jan 2016
- First submitted
- 4 Jan 2016
- Last updated
- 7 Jan 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 7 Jan 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Lifestyle Intervention to Improve in Vitro Fertilization Results
- ClinicalTrials.gov ID
- NCT02648555
- Acronym / sponsor ID
- W+D / Protocol W+D
- Conditions
- Sterility, Placenta; Implantation, Risk Reduction Behavior, Lifestyle, Neonatal Hypoglycemia
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 240 participants (estimated)
- Lead sponsor
- Hospital dos Servidores do Estado do Rio de JaneiroOther government
- Collaborators
- Gaffree & Guinle Universitary Hospital
- Study start
- May 2016
- Primary completion
- May 2018 (estimated)
- Study completion
- May 2018 (estimated)
- First posted
- 7 Jan 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Embryo adhesion and placentation depend on tissue plasminogen activator (tPA)-mediated activation of brain-derived neurotrophic factor, vascular endothelial growth factor and other growth factors, formation of hemidesmosomes, and degradation of extracellular matrix and basement membrane, either directly or by activating matrix metalloproteinases.
Since glucose and insulin stimulate release of a major tPA inhibitor by endothelial cells - plasminogen activator inhibitor (PAI)-1 - the investigators hypothesized that lifestyle interventions proven effective in maintaining glucose and insulin levels within the normal range would increase the take home baby rate in women undergoing assisted reproduction.
Detailed description
Tissue plasminogen activator (tPA) has a well-known role in the coagulation pathway. tPA converts plasminogen to plasmin. Plasmin dissolves fibrin clots, thus limiting thrombus formation to the site of vascular injury.
In the extravascular compartment, tPA is a pivotal mediator of tissue formation and remodeling. Due to its proteolytic activity, tPA participates in processes as diverse as embryo adhesion, placental angiogenesis and vasculogenesis, and neuronal plasticity. Embryo adhesion and placentation, for example, depend on tPA-mediated activation of brain-derived neurotrophic factor, vascular endothelial growth factor and other growth factors, formation of hemidesmosomes, and degradation of extracellular matrix and basement membrane, either directly or by activating matrix metalloproteinases.
Assuming low tPA activity would impair both blood clot dissolution and placentation, the investigators postulated that patients with consecutive first-trimester abortions would have a high prevalence of severe dysmenorrhea, accompanied by the passage of large clots.
In 2011, the investigators assessed the prevalence of severe dysmenorrhea during early adolescence in two groups. The first one was made of women with ≥ 2 consecutive first-trimester abortions, and the other, of women with ≥ 2 living births, and no losses or preterm deliveries. Severe dysmenorrhea was defined as suprapubic menstrual cramp, intense enough to cause repeated absenteeism from school or fainting in the absence of analgesia. Early adolescents are unlikely to use contraceptives, or to have become pregnant, two situations that may reduce the pain. In this study, severe dysmenorrhea increased the chances of having consecutive first-trimester miscarriages by sevenfold (95% Confidence Interval: 3.4 to 14.1; p<0.001).
Since glucose and insulin stimulate release of a major tPA inhibitor by endothelial cells - plasminogen activator inhibitor (PAI)-1 - the investigators hypothesized that lifestyle interventions proven effective in maintaining glucose and insulin levels within the normal range would increase the take home baby rate in women undergoing assisted reproduction.
The protocol has already been tested at a Brazilian tertiary care center in women with unexplained consecutive first-trimester abortions, conceiving spontaneously. The objective of this study was to observe the impact of lifestyle interventions on the take home baby rate, and to observe if the intervention could reduce the prevalence of preeclampsia and neonatal hypoglycemia.
From 2011 to 2015, 480 patients aged 18 to 42 years with ≥ 2 consecutive first-trimester abortions documented by pathology or ultrasonography, were randomly assigned to protocol Walking and Diet (W+D) or to standard follow-up (controls). Women were enrolled independent of having had severe dysmenorrhea during adolescence. Patients assigned to protocol W+D were instructed to walk briskly for ≥ 40 minutes seven days a week. In addition, they were recommended to avoid high-carbohydrate meals such as snacks, candies, fiber-free juices, coconut water and sugar-sweetened beverages, and to eat two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Women with antiphospholipid antibodies, second- or third-trimester losses, multiple pregnancies, anatomical abnormalities that could increase the risk of first-trimester abortions, or any condition requiring a priori anticoagulation were excluded.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard follow-up (controls) | No intervention | –Given that depressive disorders may increase the risk of spontaneous abortions, antidepressants will be not discontinued. However, expectant mothers on paroxetine or sertraline, which have been reported to increase the incidence of cardiac malformations, will be switched to fluoxetine. |
| W+D protocol (lifestyle intervention) | Experimental | Behavioral: Daily walking, Behavioral: Dietary recommendationsDaily walking and dietary recommendations. Expectant mothers on paroxetine or sertraline will be switched to fluoxetine |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- women undergoing assisted reproduction
Key exclusion criteria (6 listed)
- liver failure, kidney failure or other conditions that prevent the patient from eating proteins.
- multiple pregnancy.
- paraplegia, hemiplegia, arthropathy and other conditions that prevent the participant from exercising.
- participants lost to follow-up.
- conditions that may strongly affect pregnancy results, such as a serious accident
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Daily walkingParticipants will be instructed to walk briskly for >40 minutes, 7 days a week. | Behavioural | W+D protocol (lifestyle intervention) |
| Dietary recommendationsParticipants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks. Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron. | Behavioural | W+D protocol (lifestyle intervention) |
Primary outcome
The rate of viable pregnancies
Time frame: two years
10 secondary outcomes
The rate of fist trimester losses
Time frame: four years
The rate of second and third trimester losses
Time frame: four years
The rate of preeclampsia, eclampsia and HELLP syndrome
Time frame: four years
Cramps or bleeding during the first trimester requiring progesterone
Time frame: four years
The rate of prematurity
Time frame: four years
The rate of intrauterine growth restriction
Time frame: four years
Maternal weight gain
Time frame: four years
The rate of gestational diabetes
Time frame: four years
The rate of neonatal hypoglycemia
Time frame: four years
The rate of neonatal hyperbilirubinemia requiring phototherapy
Time frame: four years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jan 2016.
Related trials for Sterility
RecruitingObservational study
International Pilot Study for Dual Non-invasive Assesment of Embryo Development
Infertility
Active, not recruitingObservational study
Retrieval of Sperm From Men With Azoospermia Using Ultrasound-guided Rete Testis Aspiration
Azoospermia, Nonobstructive, Infertility, Male
Not yet recruiting
Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain
Low Back Pain, Chronic Low Back Pain (CLBP)
RecruitingObservational study
Impact of Infertility on the Sexual Sphere in Couples Undergoing Assisted Reproduction
Sexual Health Quality of Life, Infertile Patients
RecruitingObservational study
Pilot Study of Discarded Blastocysts
Infertility (IVF Patients)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Silvia Hoirisch-Clapauch, MD, PhD principal investigator
Hospital Federal dos Servidores do Estado, Ministry of Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Daily walking and Dietary recommendations in people with Sterility and Placenta; Implantation, run by Hospital dos Servidores do Estado do Rio de Janeiro at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Jan 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Silvia Hoirisch-Clapauch, MD, PhD (+55-21-999737500, sclapauch@ig.com.br), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The rate of viable pregnancies (time frame: two years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2016.